Company intelligence / Profile preview

Circle33

Lexington, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

AVX-470 successfully completed Phase 1b clinical trial in adults with active ulcerative colitis, demonstrating anti-TNF biological activity and proof of mechanism in IBD patients with minimal systemic exposure and low immunogenicity[1][4]. The company received orphan drug status from the FDA for pediatric IBD[1].

Therapeutic areas: Gastroenterology
Modalities: Monoclonal antibodyRecombinant protein
Industry: Biotech

Drug pipeline

2 assets

AVX-470

1 more asset in the full pipeline.

Request access →

Partnerships

Investment from online lender LendUp (approximately $30M in R&D and clinical trials)[1]

Beyond the preview

Go deeper on Circle33.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Circle33.

Explore the full profile